Skip to main content
. 2021 Nov 4;10(11):3008. doi: 10.3390/cells10113008

Figure 5.

Figure 5

Effect of AZD4547 combination on palbociclib-induced inhibition of proliferation and signaling in MCF-7/C and MCF-7/FGFR1 cells. (A) Combination with AZD4547 synergizes palbociclib-induced inhibition of cell proliferation. MCF-7/C and MCF-7/FGFR1 cells were treated with palbociclib (0, 0.625, 1.25, 2.5, 5, 10, 20 µM) ± AZD4547 (0, 0.1, 0.3, 1, 3, 9 µM) for 5 days, followed by XTT assays. The survival fractions for each cell line were normalized to the control. The combination index (CI) of palbociclib and AZD4547 from the XTT assays for each cell line was calculated using CompuSyn software. The spots with CI < 1.0 indicate synergistic effect. (B) Effect of AZD4547 and palbociclib combination on clonogenesis. The MCF-7/C and MCF-7/FGFR1 cells inoculated for clonogenic assays were treated with palbociclib (5 μM) and AZD4547 (10 μM), alone or in combination, for 2 weeks. The colonies were stained with crystal violet for imaging and analysis with Student’s t-test (** p < 0.01). (C) Western blot detection of key markers in RTK signaling and cell cycle regulation in palbociclib-treated cells. MCF-7/C and MCF-7/FGFR1 cells were treated with palbociclib (0, 5 μM, 10 μM) and AZD4547 (10 μM), alone or in combination, for 48 h, followed by Western blot analysis of specified markers.